

Cadila Pharma unveils reformulated Vasograin EC for migraine relief

08 April 2025 | News

Vasograin EC has achieved an impressive 42% growth, further cementing its position



Ahmedabad-based Cadila Pharmaceuticals has introduced Vasograin EC, a reformulated version of Vasograin with a US FDA-approved formulation. A widely trusted solution for migraine relief, now manufactured in a US FDA-approved facility that adheres to stringent global standards, highlights the company's commitment to providing trusted & quality migraine relief solutions.

Vasograin EC is formulated to deliver rapid and long-lasting migraine relief. Its reduced tablet size enhances patient compliance, comfort, and adherence, empowering individuals to regain control of their daily lives.

Over the last two years, Vasograin EC has achieved an impressive 42% growth, further cementing its position as the preferred choice for individuals seeking effective management of acute and prolonged migraine attacks. With its proven efficacy and reliability, Vasograin EC continues to lead the anti-migraine market, holding the No.1 position in the ergotamine segment with an outstanding 84% market share.

To date, over 400 crore Vasograin tablets have been sold through a network of more than 2 lakh retailers, reflecting its widespread trust and acceptance among patients and healthcare professionals.